Aktienanalyse zu Galectin Therapeutics Inc (GALT)GALTGalectin Therapeutics Inc

Galectin Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing therapies to improve the lives of patients with chronic liver disease and cancer. The Company’s drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic functions. The Company’s lead drug, belapectin, is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. The Company's additional development programs are in the treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Galectin Therapeutics Inc is not a good buy right now due to its significantly negative financial performance and technical indicators. The current price is $3.19, with a 1-year change of -37.45%, indicating a downward trend. Additionally, the RSI is at 17.639, suggesting that the stock is heavily oversold, which may lead to further declines rather than recovery in the near term.

3 analysts cover GALT: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.00.